

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known			
				Application Number		Not Yet Assigned 10/517028	
				Filing Date		Herewith	
				First Named Inventor		Johannes Evert Bunschoten	
				Group Art Unit		Not Yet Assigned	
				Examiner Name		Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number		05558.0025.PCUS00	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number – Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ – Number ⁴ – Kind Code ⁵ (if known)				
/J.H./	B1	WO 99/55357	11/04/1999	Asta Medica AG		
/J.H./	B2	WO 98/58657	12/30/1998	Akzo Nobel N.V.		
/J.H./	B3	WO 01/00227	01/04/2001	Akzo Nobel N.V.		
	B4	Chinese 1 199 042 A	11/25/1998	Asta Medica AG	No translation.	
/J.H./	B5	EP 0 788 799 A2	8/13/1997	Asta Medica AG		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
/J.H./	C1	International Search Report of Int. Appln. No. PCT/NL2003/000370	

Examiner Signature	/Jennifer Harle/	Date Considered	11/26/2007
-----------------------	------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

DM_US8053945.v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/517,028
				Filing Date	June 6, 2003
				First Named Inventor	Evert Johannes Bunschoten
				Group Art Unit	TBD
				Examiner Name	TBD
Sheet	1	of	2	Attorney Docket Number	05558.0025.PCUS00

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
/J.H./	C2	Al-Inany, H., et al., "GnRH Antagonist in Assisted Reproduction: a Cochrane Review," Human Reproduction, Vol. 17, No. 4, pp. 874-885 (2002)	
	C3	Belaisch Allart, J., et al., "Recommendations of Good Practice: Medicines that Induce Ovulation," Gynecologic Obstetric & Fertility, Vol. 31, pp. 678-686 (June 2003) No translation.	
/J.H./	C4	Burgues, S., et al., "The Effectiveness and Safety of Recombinant Human LH to Support Follicular Development Induced by Recombinant Human FSH in WHO Group I Anovulation: Evidence from a Multicentre Study in Spain," Human Reproduction, Vol. 16, No. 12, pp. 2525-2532 (2001)	
/J.H./	C5	Fausser, B., et al., "Endocrine Profiles after Triggering of Final Oocyte Maturation with GnRH Agonist after Cotreatment with the GnRH Antagonist Ganirelix during Ovarian Hyperstimulation for <i>in vitro</i> Fertilization," The Journal of Clinical Endocrinology and Metabolism, Vol. 87, No. 2, pp. 709-715 (2002)	
	C6	Hugues, J., et al., "Les Protocoles de Stimulation Ovarienne en vue de Fecundation <i>in vitro</i>: Evolution au cours des Dernieres Annees. Qu'en est il en 2003? (Evolution of Protocols for Ovarian Stimulation <i>in vitro</i> Fertilization in the Past Years. What's in Store in 2003?)" Mt. No translation. Endocrinologie et Reproduction, Vol. 5, No. 1, pp. 7-17, (2003)	
	C7	Just, A., et al., "Die Ovarielle Stimulation Und Ovulationsinduktion In Der Assistierten Reproduktion," Journal Fertil Reprod., Vol. 12, No. 4, pp. 20, 22, and 24 (2002) No translation.	
/J.H./	C8	Krusche, C., et al., "The Progesterone Antagonist Onapristone Retards the Advanced Endometrial Transformation after Gonadotropin Stimulation in Rabbits," Steroids, Vol. 65, pp. 773-782 (2000)	

Examiner Signature	/Jennifer Harle/	Date Considered	11/26/2007
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/517,028
				Filing Date	June 6, 2003
				First Named Inventor	Evert Johannes Bunschoten
				Group Art Unit	TBD
				Examiner Name	TBD
Sheet	2	of	2	Attorney Docket Number	05558.0025.PCUS00

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
/J.H./	C9	Lisi, F., et al., "Use of Recombinant Follicle-Stimulating Hormone (Gonal F) and Recombinant Luteinizing Hormone (Luperis) for Multiple Follicular Stimulation in Patients with a Suboptimal Response to <i>in vitro</i> Fertilization," Fertility and Sterility, Vol. 79, No. 4, pp. 1037-1038 (April 2003)	
/J.H./	C10	Ludwig, M., et al., "Developments in Drugs for Ovarian Stimulation," Best Practice & Research Clinical Obstetrics & Gynaecology, Vol. 17, No. 2, pp. 231-247 (2003)	
	C11	Ludwig, M., et al., "Moderne Aspekte der Reproduktionsmedizin (Modern Aspects of Reproduction Medicine)," Gynakologe 2002 Germany, Vol. 33, No. 9, pp. 861-866 (2002) No translation.	
/J.H./	C12	Ron-El, R., et al., "Induction of Ovulation after GnRH Antagonists," Human Reproduction Update 2000, <i>European Society of Human Reproduction and Embrology</i> , Vol. 6, No. 4, pp. 318-321 (2000)	
/J.H./	C13	Wikland, M., et al., "A Prospective, Randomized Comparison of Two Starting Doses of Recombinant FSH in Combination with Cetrorelix in Women Undergoing Ovarian Stimulation for IVF/ICSI," Human Reproduction, <i>European Society of Human Reproduction and Embrology</i> , Vol. 16, No. 8, pp. 1676-1681 (2001)	

Examiner Signature	/Jennifer Harle/	Date Considered	11/26/2007
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.